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Abstract 
 
Patients with chronic kidney disease (CKD) often have increased plasma cardiac troponin 
(cTn) concentration in the absence of myocardial infarction (MI). Incidence of MI is high in 
this population and diagnosis, particularly of non ST-segment elevation MI (NSTEMI), is 
challenging. Knowledge of biological variation aids understanding of serial cTn 
measurements and could improve interpretation in clinical practice. The National Academy 
of Clinical Biochemistry (NACB) recommended the use of a 20% reference change value 
(RCV) in patients with kidney failure. The aim of this study was to calculate the biological 
variation of cardiac troponin I (cTnI) and T (cTnT) in patients with moderate CKD 
(glomerular filtration rate [GFR] 30-59 mL/min/1.73 m2).  
Plasma samples were obtained from twenty patients (median GFR 43.0 mL/min/1.73 m2) 
once a week for four consecutive weeks. cTnI (Abbott ARCHITECT® i2000SR, median 4.4 
ng/L, upper 99th percentile of reference population 26.2 ng/L) and cTnT (Roche Cobas® 
e601, median 11.7 ng/L, upper 99th percentile of reference population 14 ng/L) were 
measured in duplicate using high sensitivity assays. After outlier removal and log 
transformation, eighteen patients’ data were subject to ANOVA and within-subject (CVI), 
between-subject (CVG) and analytical (CVA) variation calculated. Variation for cTnI was 
15.0%, 105.6%, 8.3% respectively and for cTnT 7.4%, 78.4%, 3.1%, respectively. RCVs for 
increasing and decreasing troponin concentrations were +60%/-38% for cTnI and +25%/-
20% for cTnT.  
The observed RCV for cTnT is broadly compatible with the NACB recommendation, but for 
cTnI larger changes are required to define significant change. The incorporation of separate 
RCVs for cTnI and cTnT, and separate RCVs for rising and falling concentrations of cardiac 
troponin, should be considered when developing guidance for interpretation of sequential 
cardiac troponin measurements.   
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Introduction  
Chronic kidney disease (CKD) is common: 4.5% of the UK population have a glomerular 
filtration rate (GFR) below 60 mL/min/1.73 m2.1 The majority of individuals with CKD have 
moderate disease (CKD category G3) defined by a GFR of 30 to 59 mL/min/1.73 m2. People 
with CKD have an increased prevalence of cardiovascular disease2,3 and an increased 
cardiovascular mortality risk with declining renal function.4-8 Consequently, patients with 
moderate CKD are more likely to die from cardiovascular complications than progress to 
renal failure requiring renal replacement therapy. 
 
Diagnosis of acute myocardial infarction requires: (a) evidence of myocardial injury by 
observing at least one measure of cardiac troponin concentration exceeding the upper 99th 
percentile of a healthy reference population;  (b) confirmation that such injury is acute, 
through observing a rise and/or fall of cardiac troponin concentration and; (c)  evidence of 
myocardial ischaemia as demonstrated by accompanying characteristic symptoms and signs 
of myocardial infarction (e.g. electrocardiogram changes).9 Patients with CKD are frequently 
observed to have concentrations of cardiac troponin that exceed the 99th percentile in the 
absence of myocardial infarction.9-12 The increased plasma troponin concentration observed 
in CKD is most likely a reflection of the multifaceted burden of cardiovascular disease and 
creates a significant diagnostic problem.9,10,13-15 The diagnosis of myocardial infarction in 
patients with CKD can be further complicated by absence of ischaemic symptoms and 
characteristic electrocardiogram changes.13,16-18 In this situation, observation of changing 
cardiac troponin concentration over time is a useful pointer towards myocardial infarction, 
although acute volume overload or heart failure may also cause this pattern.9 
 
There is little published data relating to the biological variation of cardiac troponin in patients 
with moderate CKD. Knowledge of the biological (and analytical) variation can be used to 
calculate reference change values (RCVs), which can be used to determine whether a change 
in serial measures of a biomarker are statistically significant.19 This is pertinent to the 
diagnosis of acute coronary syndromes since other medical conditions, including CKD, 
increase cardiac troponin concentrations in the absence of myocardial infarction. Defining 
significant change in cardiac troponin concentration is an area of active debate. In 2007, the 
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National Academy of Clinical Biochemistry (NACB) suggested a change of 20% should be 
considered significant amongst dialysis patients, although this recommendation predated use 
of high sensitivity cardiac troponin assays and did not consider biological variation.20 The 
recent Fourth Universal Definition of Myocardial Infarction considers the difficulties of 
defining significant change. Whilst a troponin concentration change >50% has been 
considered to exceed that which could be attributed to biological and analytical variability, 
smaller changes (>20%) are significant when the initial baseline value exceeds the 99th 
percentile of the reference population. Furthermore, there is a move towards defining change 
in absolute (concentration) rather than relative (percentage) terms, although it is 
acknowledged that such values will be assay dependent.9,21 Generally, definitions of 
significant change have not discriminated between cardiac troponin T (cTnT) and cardiac 
troponin I (cTnI). The aim of the present study was to establish the total variation (CVT), 
within-subject biological variation (CVI) and analytical variation (CVA) of cTnT and cTnI 
using high-sensitivity assays in patients with clinically stable moderate CKD in order to 
derive RCVs.   
 
Study Participants and Methods 
 
Patients were recruited from nephrology clinics at the Kent Kidney Care Centre, Canterbury, 
UK, between August 2014 and July 2015. Twenty white participants with moderate CKD 
were invited to participate in the biological variability sub-study of the multi-centre UK 
prospective longitudinal eGFR-C study.22 Inclusion criteria comprised an estimated GFR 
between 30 and 59 mL/min/1.73 m2 sustained over at least 90 days prior to the study. GFR 
was estimated using the Modification of Diet in Renal Disease (MDRD) Study equation23 and 
an enzymatic creatinine assay (Abbott Laboratories) standardised to the reference materials 
NIST SRM 967 and 914. Exclusion criteria were age <18 years, pregnancy, breastfeeding, an 
episode of acute kidney injury within the last six months, known current alcohol or drug 
abuse, amputee (whole or part-limb), kidney transplant recipient and cognitive impairment. 
Patients provided written informed consent. The study had ethical approval (South-East Coast 
Research Ethics Committee, reference 11/LO/1304). The study conforms to the 
internationally agreed checklist for the reporting of studies of biological variation.24 
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Blood was collected into ethylenediaminetetraacetic acid (EDTA) (Vacuette®, Greiner Bio-
One International) tubes using standard venepuncture procedures. Samples were obtained 
once a week for four consecutive weeks with standardisation to the same time of day 
(morning) and day of the week to minimize pre-analytical variables. Samples were 
centrifuged within 6 hours of venepuncture and plasma pipetted into 2 mL microtubes 
(Sarstedt). Plasma was stored at -80oC for approximately 24 months before cardiac troponins 
were measured in a single batch.  
 
Cardiac troponins were measured in duplicate using two high-sensitivity assays. On the 
morning of analysis, samples were thawed at room temperature and mixed by inversion. 
Immediately prior to analysis, samples were centrifuged at 3,300 g for 10 minutes. Plasma 
cTnI was measured using the ARCHITECT® STAT high-sensitivity cTnI chemiluminescent 
microparticle immunoassay (Abbott Laboratories, Chicago, Illinois, USA, product code 
3P25) assay (99th percentile of a healthy reference population: female (15.6 ng/L), male (34.2 
ng/L), combined (26.2 ng/L)) on the Abbott ARCHITECT® i2000SR module. Plasma cTnT 
was measured using the Elecsys® high-sensitivity cTnT electrochemiluminescent sandwich 
immunoassay on the Roche Cobas® e601 (Roche Diagnostics, Risch-Rotkreuz, Switzerland) 
analyser platform (99th percentile of a healthy reference population 14 ng/L). The 
measurement of both cardiac troponins was undertaken on the same day by a single operator 
using one instrument that had been calibrated using a single batch of standards, reagents and 
quality controls. The samples for each patient were analysed in duplicate in random order to 
minimise any effects of assay drift.  
Data analysis 
Samples with measures below the limit of detection for either the cTnI assay (<1.2 ng/L) or 
the cTnT assay (<5 ng/L) were excluded. Normality was assessed using the Shapiro-Wilk test 
(Analyse-it Software Ltd., Leeds, UK) which showed a non-Gaussian distribution. The data 
were therefore log-transformed using a natural logarithm as recommended.24,25 For both 
cardiac troponins, Cochran’s test identified two values that differed markedly between 
duplicate measures and one value that differed markedly between the series of replicate 
measures; these were therefore removed. Where one duplicate of a sample was excluded (or 
absent), both duplicate results were excluded from statistical analysis.26 The dataset of each 
patient was then subject to outlier removal by Reed’s test; no subjects were excluded based 
on this test. The dataset belonging to any patient with less than three (out of four) duplicate 
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cardiac troponin measures available were completely excluded from statistical analysis. On 
this basis, a total of three patients were excluded; one individual was excluded from all 
analysis; one individual was excluded from cTnI analysis only and one individual was 
excluded from cTnT analysis only. Details of excluded measures are shown in supplementary 
table S1. The log-transformed data from 18 patients were subject to ANOVA (Minitab 
Statistical Software, Minitab Ltd, Coventry, UK) and estimates of biological variation were 
generated for CVT, CVA and CVI. Data was then back-transformed allowing derivation of the 
exact CV values [[√exp(S2) − 1 × 100].27 Power (>80%)28 and width of confidence 
intervals (CI) for the CVI
29
 were estimated according to standard methods. Calculation of 
bidirectional (positive and negative) RCV’s was appropriate for the definition of acute 
myocardial infarction (a rise and/or fall in cardiac troponin). Furthermore, since it cannot be 
assumed that the positive RCV (rise) is the same as the negative RCV (fall), asymmetrical 
(log-normal) RCV’s were calculated using the approach for log-normal data proposed by 
Fokkema.25  
  
Results 
 
Characteristics of the study participants are shown in Table 1. Three patients had type 2 
diabetes mellitus, seven ischaemic heart disease, one angina and two had heart failure. One 
participant was a current smoker and 10 were ex-smokers. Antihypertensive and cholesterol-
reducing drugs were being taken by 15 and 13 patients, respectively. Seven of the participants 
had urine albumin concentrations between 3 and 30 mg/mmol creatinine, and a further four 
had urine albumin concentrations >30 mg/mmol. No participants had a significant change in 
kidney function during the study nor an acute cardiac event.30 
 
The median concentration overall (all patients, all study points) of both cardiac troponins was 
below the relative 99th percentile derived from a healthy reference population. For cTnT the 
median cTnT concentration of seven patients exceeded the 99th percentile (Fig 1.A) whereas 
for cTnI, no individual patient had a median concentration over all study points exceeding the 
99th percentile (Fig 1.B). The highest median concentration of cTnT observed in an individual 
was 37.6 ng/L whereas the highest median value for an individual for cTnI was 13.7 ng/L.  
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Biological and analytical variation data are shown in Table 2. The within-subject and 
analytical variability of cTnT was approximately half that of cTnI. Consequently, the positive 
and negative RCV’s were lower for cTnT (25%/-20%) than for cTnI (60%/-38%).  
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Discussion  
 
Defining a statistically significant change in serial troponin concentrations should be 
established from biological variability studies.31 There is a literature describing the biological 
variation of cardiac troponins in patients with kidney failure treated by dialysis but, to the 
best of our knowledge, this is the first study to report the biological variation of both cTnI 
and cTnT measured using high-sensitivity assays in patients with moderate CKD. We 
observed within-subject biological variation of 7.4% (CI 5.6% to 9.2%) and 15.0% (CI 11.3% 
to 18.7%) for cTnT and cTnI, respectively. RCVs for increasing and decreasing troponin 
concentrations were +25%/-20% for cTnT and +60%/-38% for cTnI. 
 
The estimates of within-subject biological variation for cardiac troponin reported in the 
present study are similar to those previously reported in patients undergoing haemodialysis. 
For example, Fahim et al reported a CVI for cTnT of 7.9% in dialysis patients.
32 Among 
studies that simultaneously measured both cTnI and cTnT,33,34 including the present study, 
the within-subject variability has been consistently lower for cTnT than for cTnI. In patients 
with renal failure undergoing haemodialysis treatment Mbagaya et al reported slightly higher 
CVI values compared to the present study for cTnT and cTnI of 10.5% and 20.2% 
respectively.34 Aakre et al estimated the CVI of cardiac troponins amongst stable 
haemodialysis patients and reported values of 8.3% and 15.6% for cTnT and cTnI 
respectively. In the same study CVI values amongst healthy individuals of 8.3% (cTnT) and 
14.3% (cTnI) were reported.33 Corte et al observed within-subject biological variation for 
cTnT of 14.7% amongst patients with kidney failure compared to 5.9% amongst healthy 
individuals, although the study design was somewhat different between the two groups.35 
Amongst patients with CKD not receiving dialysis (median estimated GFR 17 mL/min/1.73 
m2), within-day biological variability for cTnI of 8% to 9% has been reported.36 Overall, 
reported variability appears comparable between studies including haemodialysis patients, 
CKD patients and healthy individuals.  
When considering any change in a patient’s results, healthcare practitioners need to be able to 
distinguish true change (‘signal’) from the ‘noise’ of variability. In clinical practice, 
biological variation is best considered in terms of the RCV, which takes both biological and 
analytical variation into account. RCV’s for cTnT in the present study (25%/-20%) are 
generally comparable to those previously reported in dialysis patients: 33%/-25%,32 26%/-
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21%33 and 34%/-26%.34 The RCV’s for cTnT reported in the present study are also broadly 
compatible with the NACB’s definition of a significant change of 20%.20 
 
For cTnI, however, our data suggests a larger difference (60%/-38%) is required to define 
significant change. Similarly, reported RCV’s for cTnI amongst dialysis patients were 53%/-
35%33 and 80%/-44%,34 and amongst CKD patients not receiving dialysis 34%/-26%.36 The 
reported positive and negative RCV values therefore consistently exceed the 20% critical 
difference recommended by the NACB, in some cases by several fold, and would stretch the 
critical relative differences discussed within the Fourth Universal Definition of Myocardial 
Infarction.9,20 Use of a 20% critical difference to interpret serial measures of cTnI could 
contribute to misleading diagnoses of acute myocardial infarction in patients with moderate 
CKD. It is also clear that the data does not have a symmetric distribution, i.e. the same 
critical difference cannot be applied to rising and falling troponin concentrations. Our data 
and that of others,33,34,36 particularly for cTnI, demonstrate that the biological variation of 
troponin concentration is non-Gaussian and that RCVs will differ between rising and falling 
concentrations. Similarly, should absolute, as opposed to relative, delta values be used to 
detect change, as has been suggested, the same issue will pertain regarding different rising 
and falling troponin concentrations.9 
As previously reported, particularly amongst dialysis patients,32-34 but also in earlier studies 
of non-dialysis CKD patients,10,11 cTnT is more commonly increased above the 99th 
percentile than cTnI. The reason for this is not the main focus of the present study but various 
explanations have been proposed including different cTnI and cTnT release kinetics or 
differences in clearance from the circulation. This observation is reinforced by the present 
study with concentrations of cTnT commonly exceeding the 99th percentile reference interval 
whilst cTnI concentrations were predominantly normal.  
 
The study was adequately powered based on essential elements of the study design (number 
of individuals, samples and replicates).28 In relation to analytical performance specifications 
defined by the ratio of CVA to CVI, the cTnT (0.4) and cTnI (0.5) assays met desirable and 
minimum quality specifications respectively.26 The study followed a strict design to minimise 
pre-analytical and analytical variation and investigator bias.24 Outliers in the data were 
excluded using a formal exclusion protocol and a strength of this study is that few data were 
excluded prior to ANOVA. Estimation of components of variation was derived using a nested 
10 
 
ANOVA approach, which takes into account analytical variation for estimation of within-
subject biological variation. The participants were derived from a patient group which is a 
major population in which detection of myocardial infarction is a clinically relevant issue. 
Participants had stable kidney disease, suggesting that the variation we have reported is 
physiological and not pathological in nature. The methods used to measure cTnT and cTnI 
met criteria for the definition of high-sensitivity assays31,37 and are recommended by the 
National Institute for Health and Care Excellence (NICE) for the early rule out of myocardial 
infarction.38  
Our study has some limitations. The cohort studied was recruited from a single centre and 
was exclusively Caucasian: biological variability estimates may therefore not be transferable 
to other ethnic groups. Our study comprised participants with moderate CKD and the results 
may not be transferable to more advanced kidney disease. However, as discussed above, 
comparison with other studies of patients receiving dialysis for kidney failure suggests 
similar levels of biological variability.32-34 The RCV is a value derived under idealised 
conditions which are often not replicated in typical clinical practice (e.g. multiple operators 
and batches of reagents will increase the value of CVA and hence increase the RCV). 
Furthermore, sampling time was standardised to some extent in our study. In the clinical 
setting change in cTnT concentrations will also be influenced by the known circadian 
variation, with peak concentrations occurring in the early morning and a nadir in the 
evening.39,40 RCVs should therefore be considered a minimum clinically significant change. 
Individual laboratories may need to adjust RCVs to take into account the analytical variation 
of their own troponin assay. However, the values generated in this study are useful to guide 
understanding of change in cardiac troponin concentration in patients among whom 
interpretation can often be challenging. Although the recommended approach, the outlier 
removal process may inadvertently remove values representing true biological variation, 
albeit, as noted above, relatively few outliers were removed in this study. Myocardial 
infarction was not a measured outcome in this cohort of CKD patients. However, in a renal 
dialysis population, Aakre et al demonstrated successful use of the RCV to identify patients 
with acute cardiac events.33 Serial changes in concentration of cTnT exceeded the RCV in all 
four patients who experienced cardiac events and in three of four patients for cTnI.33 Finally, 
our samples were stored for up to 2 years at -80oC prior to analysis. We are unaware of 
published data supporting storage over this period. However, Egger et al report good stability 
over one year at -80oC for both cTnI and cTnT in EDTA plasma, including through two 
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freeze-thaw cycles, measured using the Abbott and Roche assays respectively, suggesting 
good stability of these markers.41 
A further consideration is the timescale over which variability is studied to generate the RCV. 
We have used samples obtained at weekly intervals. Variability over shorter periods of time 
may be more relevant when addressing the issue of diagnosis of myocardial infarction. 
Amongst healthy volunteers, for both cTnT and cTnI, within-subject biological variability 
does seem to be higher when studies are conducted over periods of days/weeks compared to 
studies of within-day (hourly) variability.33,42,43 Literature on this point is less clear amongst 
patients with kidney disease. Aakre et al studied variability in haemodialysis patients and 
observed lower within-subject variability when troponins were studied at 90 minute intervals 
over six hours (cTnT 1.9% and cTnI 3.3%).33 Conversely, estimates of CVI for cTnI obtained 
by van der Linden et al from hourly measurements over 24 h in patients with and without 
CKD were 8.7% and 9.4% respectively, closer to the results we report in the present study.36 
These authors observed that the CVI did not differ significantly irrespective of whether 
hourly, 3-hourly, or 6-hourly sampling intervals were considered.36 
In conclusion, we describe the biological variability of cTnT and cTnI in a carefully designed 
study using high sensitivity assays in patients with moderate CKD. Our data suggests that 
independent RCV’s for cTnI and cTnT should be incorporated into guidance for the 
interpretation of cardiac troponin in patients with CKD. Furthermore, we recommend that 
separate positive and negative RCV’s should be considered, particularly for cTnI. Whilst not 
the focus of our study, the same considerations would apply to the use of absolute 
concentration changes. Research should continue to elucidate reasons for the observed 
difference in prevalence of increased concentrations of cTnT compared to cTnI in relation to 
the respective 99th percentile of a healthy reference population, and of the difference in 
biological variability between the two troponins, which cannot currently be explained. 
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Table 1. Characteristics of the study population. Corresponding values for continuous data 
are shown as median (range). Laboratory median data (serum creatinine, estimated GFR and 
plasma cardiac troponin concentrations) represent the median of all values obtained during 
the four week study period. 
n 20 
Age, years 71 (50-80) 
M:F 10:10 
Caucasian (n) 20 
Height, cm 170.5 (154-194) 
Weight, kg 79.5 (47.1-118.1) 
Body surface area, m2 1.99 (1.42-2.47) 
Body mass index (median of the individual BMI values) 28.2 (19.6-40.9) 
Serum creatinine, µmol/L 124 (79-182) 
Estimated GFR calculated using MDRD equation, mL/min/1.73 m2 42.2 (31.5-61.4) 
Plasma cardiac troponin I 
Median concentration, ng/L 
Minimum concentration, ng/L 
Maximum concentration, ng/L 
Number of patients with median cTnI >appropriate 99th percentile 
 
 
4.3 
1.3 
17.3 
0/18 
Plasma cardiac troponin T 
Median concentration, ng/L 
Minimum concentration, ng/L 
Maximum concentration, ng/L 
Number of patients with median cTnT concentration >99th 
percentile 
 
11.8 
4.9 
39.6 
7/18 
 
 
 
18 
 
 
Table 2. Summary of the components of variation of cardiac troponin I and T.  
 
Components of Variation Cardiac Troponin I Cardiac Troponin T 
 
Analytical variation (CVA) 
 
8.3% (7.0%, 10.2%) 
 
3.1% (2.6%, 3.8%) 
Within-subject variation (CVI) 15.0% (11.6%, 20.2%) 7.4% (5.9%, 9.8%) 
Between-subject variation (CVG) 105.6% (72.0%, 210.8%) 78.4% (55.6%, 139.4%) 
Total variation (CVT) 17.2% 8.0% 
Positive log-normal RCV (rise) 60% 25% 
Negative log-normal RCV (fall) -38% -20% 
   
  
 
 
Values are % (95% CI); CI = confidence interval; CVA = analytical variation; CVG = 
between-subject biological variation; CVI = within-subject biological variation; RCV = 
reference change value. 
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Fig. 1. Plots depicting the biological variation of cardiac troponins T (A) and I (B) in 18 
patients (minus exclusions) with moderate CKD sampled over a period of 4 weeks.  
Diamonds represent the individual patient medians with the filled circles representing 
individual minimum and maximum values. Males and females are depicted by blue and red 
diamonds respectively. For cardiac troponin T, the horizontal dashed line represents the upper 
99th percentile of a healthy reference population. In the case of cardiac troponin I, the 
horizontal dashed line represents the 99th percentile for females (15.6 ng/L), with males 
having a higher 99th percentile (34.2 ng/L, not shown). 
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Supplementary File 
 
Supplementary Table S1. Outliers are represented in this table by patient ID number (e.g. B10551) and week of sample (e.g. week 1=A, week 
2=B etc). 
Marker Insufficient or 
missing samples 
Only one 
measure 
available 
Measurements 
less than the LoD 
Less than three 
duplicate 
measurements 
available 
Outliers 
amongst 
variances of 
duplicates 
Outliers 
amongst 
variances of 
replicates 
Outliers 
amongst 
subjects 
Cardiac 
troponin I 
B12047 (D) 
B15446 (B) 
B15222 (D) 
B13185 (A) 
B12047 (C) 
B19944 (A)  
B12062 (B) 
B15446 (C & D) 
B12047  
B15446 
B12435 (B) 
B13607 (C) 
B10934 (D) 
 
n/a 
Cardiac 
troponin T 
n/a B12880 (B, C & D) 
B15446 (D) 
B12880 
B15446 
B10934 (C) 
B12435 (A) 
B12047 (B) 
 
n/a 
 
LoD, limit of detection 
 
 
 
